TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocadâ"¢ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 4, 2026, after the close of market. Financial results will be released at 4:00 p.m. ET (2:0. ...

Core Insights - Align Technology, Inc. showcased its latest innovations in digital dentistry at the Greater New York Dental Meeting (GNYDM) 2025, emphasizing its commitment to enhancing treatment planning and patient experiences through advanced technology [1] Company Innovations - Align Technology presented the Align™ Digital Platform, which integrates software, systems, and services for a seamless workflow among doctors, labs, patients, and consumers [1] - The iTero Lumina™ scanner was highlighted for its 3x larger field of view and ability to scan 2x faster, improving efficiency in capturing complex dental cases [1] - The Align™ Oral Health Suite was introduced, featuring tools for personalized oral health reports to enhance patient engagement [1] - Invisalign Smile Architect™ software now includes Multiple Treatment Plans, allowing for side-by-side comparison of orthodontic and restorative options [1] - The iTero™ Design Suite aims to improve practice efficiency and patient experiences by streamlining the design process for in-practice 3D printing [1] - ClinCheck® Signature experience offers a faster, tailored approach to treatment planning, enhancing the overall workflow for dental professionals [1] Educational Initiatives - Align Technology sponsored clinical education sessions led by industry experts, focusing on practice productivity, diagnosis simplification, and modern patient education [1]

Financial Data and Key Metrics Changes - Q3 total revenues were $996 million, reflecting a 1.8% year-over-year increase and a 1.7% sequential decrease [5][20] - Q3 non-GAAP operating margin was 23.9%, exceeding the outlook of approximately 22% [5][28] - Q3 net income per diluted share was $2.61, up $0.11 sequentially and up $0.26 year-over-year [30] Business Line Data and Key Metrics Changes - Q3 clear aligner revenues were $806 million, a 2.4% year-over-year increase [6][20] - Q3 systems and services revenues were $190 million, down 8.6% sequentially and down 0.6% year-over-year [22][25] - Q3 clear aligner volume was 648,000 cases, a 5% year-over-year increase [6][9] Market Data and Key Metrics Changes - Clear aligner volumes increased year-over-year in APAC and EMEA regions, while North America showed mixed results [10][14] - Q3 clear aligner volumes for teens and kids saw a 14.7% sequential increase, driven by strength in APAC, North America, and Latin America [14][15] - DSO performance grew double digits year-over-year, particularly in EMEA and APAC regions [13][14] Company Strategy and Development Direction - The company is focusing on enhancing digital workflow innovations and expanding its product portfolio to drive long-term growth [5][37] - Investments in AI-powered treatment planning and direct 3D printing of aligners are key to improving outcomes and efficiency [37] - The company aims to navigate headwinds in the U.S. dental market by supporting doctor customers with localized marketing and education [38] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth in clear aligners and digital scanning solutions, despite mixed results in the North American retail channel [37] - The company anticipates Q4 2025 worldwide revenues to be in the range of $1.025 billion to $1.045 billion, indicating sequential growth [33] - For fiscal 2025, the company expects clear aligner volume growth to be mid-single digits and revenue growth to be flat to slightly up from 2024 [34] Other Important Information - The company has partnered with Healthcare Finance Direct to enhance affordability for patients seeking Invisalign treatment [11][85] - As of September 30, 2025, cash and cash equivalents were $1.004 billion, with a share repurchase plan in place [30][31] Q&A Session Summary Question: Comments on early Q4 market conditions and ClinCheck launch impact on gross margins - Management noted positive sentiment from Q3 and highlighted the efficiency improvements expected from the new ClinCheck technology [42][44] Question: Clarification on ASP trends and pricing environment - ASP was impacted by geographic mix, with expectations for improvement in Q4 as Europe contributes more to total sales [51][53] Question: Factors affecting North American retail demand - Management indicated that economic issues are affecting retail customers more than DSOs, and efforts will focus on localized marketing to drive demand [64][65] Question: Year-over-year growth in EMEA and APAC markets - Management confirmed double-digit growth in both regions, with strong performance across various countries [70][72] Question: Insights on the Healthcare Finance Direct partnership - The partnership is helping to increase patient conversions, with more doctors utilizing the financing option [85] Question: Competitive landscape in China and VBP implications - Management is aware of the VBP developments and is positioning the company accordingly, though specifics remain unclear [90][91]

Core Insights - Align Technology, Inc. is a leader in digital orthodontics and restorative dentistry, with a market capitalization of nearly $9.2 billion and a product portfolio that includes Invisalign clear aligners, iTero intraoral scanners, and exocad CAD/CAM software [1] Financial Performance - The company is expected to report a profit of $1.90 per share for Q3 fiscal 2025, representing a 12.4% year-over-year increase from $1.69 per share in the same period last year [3] - Analysts project that EPS for fiscal 2025 will rise by 15.8% year-over-year to $8.12, with an additional 8.1% increase anticipated in fiscal 2026 to $8.78 [5] Recent Challenges - Align Technology faced challenges in Q2 due to uneven patient case conversion, economic uncertainties including U.S. tariff impacts, and less accessible financing for orthodontic treatments, leading to a softer seasonal uptick in case starts [4] - The company has missed Wall Street EPS estimates in three of the past four quarters, only surpassing them once [3] Market Performance - Align Technology's shares have underperformed the broader market, declining 45.9% over the past 52 weeks and 38.3% year-to-date, while the S&P 500 Index gained 17.6% over the past year [6] - Compared to the S&P 500 Healthcare Sector SPDR, which fell 6.4% over the past 52 weeks but gained 4.1% year-to-date, Align's stock performance has been notably weaker [6] Strategic Focus - Management is implementing strategies to cut costs smartly, boost efficiency, and ensure long-term growth as part of their playbook for the second half of 2025 [4]